Jun. 4 at 8:21 AM
$RENB No good deed goes unpunished !
The spike in volume yesterday - aligns perfectly with what we have seen previously: No matter how many good news we have seen this spring - all news has been used to start a sell-off….:(
$RENB obtained a key U.S. patent for AI-driven drug discovery and diagnostics. It is a VERY important patent,
because the patent represents a strategic milestone. It enhances the technological capabilities and reinforces the commitment to advancing AI-powered solutions in both drug discovery and diagnostics
How is that ?
1. By data Integration and harmonization: The patent introduces innovative methods for integrating and standardizing diverse biomedical data sources—including genomics, electronic health records, imaging, and clinical trial data—into a cohesive framework. This addresses a critical challenge in pharmaceutical R&D: the fragmentation of data across various platforms and formats.
2. Scalable Predictive Analytics: By operating across distributed and parallel computing environments, the patented methods will enable real-time, reproducible predictive analytics at scale. This scalability is essential for handling the vast and complex datasets typical in biomedical research, thus makingaccurate drug discovery processes much faster and efficient.
3. Strengthens RENB's Intellectual Property Portfolio: This new patent builds upon Renovaro's existing IP, which focuses on machine learning pipeline optimization.
Renovaros believes that the patent will solidify Renovaro's position in the competitive landscape of AI-driven biomedical research, and importantly, it will be a robust foundation for commercial partnerships and licensing opportunities.
4. Strategic Alignment with Recent Acquisitions:
This proves that Renovaro's recent merger with BioSymetrics, is nothing less than brilliant. BioSymetrics' proprietary Elion Platform and Renovaro's Cube enhances the company's capabilities in precision medicine
5. Market Expansion and Revenue Growth: The patented technology positions Renovaro to capitalize on the growing demand for data-driven therapeutics. By enabling more efficient drug discovery and diagnostics, RENB can expand its market presence and pursue new revenue streams through product development and strategic collaborations with large companies such as Merck, Pfizer and Deerfield.
Back to yesterdays trading: :)
The unusual trading volume surge for
$RENB, reaching 77 million shares—77 times the average. HFT showed 45 million shares traded within 30 minutes after the price surged from 30 to 45 cents on low volume
This drew attention from daytraders, including short sellers, probably also because, as we all know, RENB still faces challenges like being Nasdaq non-compliance, (with the minimum bid price requirement); and also renewed concern about Russell2000 participation
The patent news sparked volatility, attracting short sellers betting on a potential drop after the surge, especially given RENB's weak financial health and the potentially terminated merger with Predictive Oncology in April 2025.
(
$POAI claims they will win in Court - as do
$RENB)
Over all, the broader market context shows increased shorting activity in 2025, with hedge funds targeting discretionary stocks amid economic downturn fears (Reuters, April 22, 2025), which certainly have amplified bearish sentiment toward a speculative micro-cap like RENB - but as the say "all this will pass..." :)
